IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis

Journal of Clinical Investigation

Volumn 114, Issue 3, 2004, Pages 427-437

  Binder, Christoph J ^a,c   Hartvigsen, Karsten ^a   Chang, Mi Kyung ^a   Miller, Marina ^a   Broide, David ^a   Palinski, Wulf ^a   Curtiss, Linda K ^b   Corr, Maripat ^a   Witztum, Joseph L ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYTOKINE; EPITOPE; GAMMA INTERFERON; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 5; LIPOPROTEIN; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID; PHOSPHORYLCHOLINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FAST PROTEIN LIQUID CHROMATOGRAPHY; FEMALE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIBODY FORMATION; ARTERIOSCLEROSIS; BONE MARROW TRANSPLANTATION; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; IMMUNITY, NATURAL; IMMUNOGLOBULIN M; INTERLEUKIN-5; LIPOPROTEINS, LDL; MALONDIALDEHYDE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; TH2 CELLS;

EID: 4043152981     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200420479     Document Type: Article

References (65)

1. Steinberg, D. 2002. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat. Med. 8:1211-1217.
2. Glass, C.K., and Witztum, J.L. 2001. Atherosclerosis: the road ahead. Cell. 104:503-516.
3. Binder, C.J., et al. 2002. Innate and acquired immunity in atherogenesis. Nat. Med. 8:1218-1226.
4. Hansson, G.K., Libby, P., Schonbeck, U., and Yan, Z.Q. 2002. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 91:281-291.
5. Hörkkö, S., et al. 2000. Immunological responses to oxidized LDL. Free Radic. Biol. Med. 28:1771-1779.
6. Palinski, W., et al. 1996. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J. Clin. Invest. 98:800-814.
7. Hörkkö, S., et al. 1999. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adduces inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103:117-128.
8. Shaw, P.X., et al. 2000. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Infest. 105:1731-1740.
9. Friedman, P., Hörkkö, S., Steinberg, D., Witztum, J.L., and Dennis, E.A. 2002. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol concentration. J. Biol. Chem. 277:7010-7020.
10. Briles, D.E., Forman, C., Hudak, S., and Claflin, J.L. 1982. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J. Exp. Med. 156:1177-1185.
11. Harnett, W., and Harnett, M.M. 1999. Phosphorylcholine: friend or foe of the immune system? Immunol. Today. 20:125-129.
12. Binder, C.J., et al. 2003. Pneumococcal vaccination decreases atherosclerotic lesion formation: Molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9:736-743.
13. Palinski, W., Miller, E., and Witztum, J.L. 1995. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. U. S. A. 92:821-825.
14. Freigang, S., Hörkkö, S., Miller, E., Witztum, J.L., and Palinski, W. 1998. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vasc. Biol. 18:1972-1982.
15. George, J., et al. 1998. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis. 138:147-152.
16. Zhou, X., Caligiuri, G., Hamsten, A., Lefvert, A.K., and Hansson, G.K. 2001. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21:108-114.
17. Hansson, G.K. 2001. Immune mechanisms in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21:1876-1890.
18. Palinski, W., et al. 1989. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. U. S. A. 86:1372-1376.
19. Palinski, W., Tangitala, R.K., Miller, E., Young, S.G., and Witztum, J.L. 1995. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15:1569-1576.
20. Palinski, W., et al. 1994. ApoE-deficienc mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 14:605-616.
21. Zhou, X., Paulsson, G., Stemme, S., and Hansson, G.K. 1998. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J. Clin. Invest. 101:1717-1725.
22. Lee, T.S., Yen, H.C., Pan, C.C., and Chau, L.Y. 1999. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol 19:734-742.
23. Huber, S.A., Sakkinen, P., David, C., Newell, M.K., and Tracy, R.P. 2001. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation. 103:2610-2616.
24. King, V.L., Szilvassy, S.J., and Daugherty, A. 2002. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- mice. Arterioscler. Thromb. Vasc. Biol. 22:456-461.
25. Davenport, P., and Tipping, P.G. 2003. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 163:1117-1125.
26. Mallat, Z., et al. 1999. Protective role of interleukin-10 in atherosclerosis. Circ. Res. 85:E17-E24.
27. Pinderski, L.J., et al. 2002. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ. Res. 90:1064-1071.
28. Billiau, A., and Matthys, P. 2001. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J. Leukoc. Biol. 70:849-860.
29. Kearney, J.F., Barletta, R., Quan, Z.S., and Quintans, J. 1981. Monoclonal vs. heterogeneous anti-H-8 antibodies in the analysis of the antiphosphorylcholine response in BALB/c mice. Eur. J. Immunol. 11:877-883.
30. Snapper, C.M., et al. 2001. Distinct types of T-cell help for the induction of a humoral immune response to Streptococcus pneumoniae. Trends Immunol. 22:308-311.
31. Takatsu, K. 1998. Interleukin 5 and B cell differentiation. Cytokine Growth Factor Rev. 9:25-35.
32. Kopf, M., et al. 1996. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity. 4:15-24.
33. Erickson, L.D., Foy, T.M., and Waldschmidt, T.J. 2001. Murine B1 B cells require IL-5 for optimal T cell-dependent activation. J. Immunol. 166:1531-1539.
34. Robertson, A.K., Zhou, X., Strandvik, B., and Hansson, G.K. 2004. Severe hypercholesterolaemia leads to strong Th2 responses to an exogenous antigen. Scand. J. Immunol. 59:285-293.
35. Gupta, S., et al. 1997. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest. 99:2752-2761.
36. -/- mice. J. Interferon Cytokine Res. 22:661-670.
37. Song, L., Leung, C., and Schindler, C. 2001. Lymphocytes are important in early atherosclerosis. J. Clin. Invest. 108:251-259. doi:10.1172/JCI200111380.
38. Frostegard, J., et al. 1999. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 145:33-43.
39. Schönbeck, U., Sukhova, G.K., Gerdes, N., and Libby, P. 2002. T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm. Am. J. Pathol. 161:499-506.
40. Yamaguchi, Y., et al. 1988. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J. Exp. Med. 167:1737-1742.
41. Yamaguchi, Y., et al. 1988. Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J. Exp. Med. 167:43-56.
42. Lasser, E.C., Berry, C., and Kortman, K. 1987. Diminished atherosclerotic arterial calcifications in asthma. A possible role for elevated endogenous heparin-like material. Allergy. 42:549-552.
43. Wetzel, G.D. 1989. Interleukin 5 regulation of peritoneal Ly-1 B lymphocyte proliferation, differentiation and autoantibody secretion. Eur. J. Immunol. 19:1701-1707.
44. Nisitani, S., Tsubata, T., Murakami, M., and Honjo, T. 1995. Administration of interleukin-5 or -10 activates peritoneal B-1 cells and induces autoimmune hemolytic anemia in anti-erythrocyte autoantibody-transgenic mice. Eur. J. Immunol. 25:3047-3052.
45. Sakiyama, T., Ikuta, K., Nisitani, S., Takatsu, K., and Honjo, T. 1999. Requirement of IL-5 for induction of autoimmune hemolytic anemia in anti-red blood cell autoantibody transgenic mice. Int. Immunol. 11:995-1000.
46. Tominaga, A., et al. 1991. Transgenic mice expressing a B cell growth and differentiation factor gene (interleukin 5) develop eosinophilia and autoantibody production. J. Exp. Med. 173:429-437.
47. Yoshida, T., et al. 1996. Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5R alpha-deficient mice. Immunity. 4:483-494.
48. Berland, R., and Wortis, H.H. 2002. Origins and functions of B-1 cells with notes on the role of CD5. Annu. Rev. Immunol. 20:253-300.
49. Tominaga, A., et al. 1989. Establishment of IL-5-dependent early B cell lines by long-term bone marrow cultures. Growth Factors. 1:135-146.
50. Ishida, H., Hastings, R., Kearney, J., and Howard, M. 1992. Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1 B cells but not conventional B cells. J. Exp. Med. 175:1213-1220.
51. O'Garra, A., et al. 1992. Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur. J. Immunol. 22:711-717.
52. Vogel, L.A., Lester, T.L., Van Cleave, V.H., and Metzger, D.W. 1996. Inhibition of murine B1 lymphocytes by interleukin-12. Eur. J. Immunol. 26:219-223.
53. Bendelac, A., Bonneville, M., and Kearney, J.F. 2001. Autoreactivity by design: innate B and T lymphocytes. Nat. Rev. Immunol. 1:177-186.
54. Chang, M.K., et al. 1999. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc. Natl. Acad. Sci. U. S. A. 96:6353-6358.
55. Major, A.S., Fazio, S., and Linton, M.F. 2002. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 22:1892-1898.
56. Stall, A.M., Wells, S.M., and Lam, K.P. 1996. B-1 cells: unique origins and functions. Semin. Immunol. 8:45-59.
57. Kearney, J.F. 2000. Immune recognition of OxLDL in atherosclerosis [comment]. J. Clin. Invest. 105:1683-1685.
58. Caligiuri, G., Nicoletti, A., Poirier, B., and Hansson, G.K. 2002. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J. Clin. Invest. 109:745-753. doi:10.1172/ JCI200207272.
59. Leckie, M.J. 2003. Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models. Am. J. Respir. Med. 2:245-259.
60. Danzig, M., and Cuss, F. 1997. Inhibition of interleukin-5 with a monoclonal antibody attenuates allergic inflammation. Allergy. 52:787-794.
61. Schiller, N.K., Kubo, N., Boisvert, W.A., and Curtiss, L.K. 2001. Effect of gamma-irradiation and bone marrow transplantation on atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21:1674-1680.
62. Li, A.C., et al. 2000. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106:523-531.
63. Tangirala, R.K., Rubin, E.M., and Palinski, W. 1995. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid. Res. 36:2320-2328.
64. Zlot, C.H., et al. 1999. Generation of monoclonal antibodies specific for mouse apolipoprotein B-100 in apolipoprotein B-48-only mice. J. Lipid. Res. 40:76-84.
65. Wetzel, G.D. 1991. Induction of interleukin-5 responsiveness in resting B cells by engagement of the antigen receptor and perception of a second polyclonal activation signal. Cell Immunol. 137:358-366.